The natural estrogen 171-estradiol (E2) has a profound influence on proliferation and neoplastic transformation of mammary epithelium. The role of cellular metabolism of E2 in mammary carcinogenesis, however, remains to be elucidated. Explant culture and cell culture models developed from noncancerous human mammary tissue were used to examine modulation of E2 metabolism in response to treatment with prototype rodent mammary carcinogens and the ability of the naturally occurring phytochemical indole-3-carbinol (13C) to influence E2 metabolism and regulate aberrant proliferation. In the two models, treatment with the chemical carcinogens 7,12-dimethylbenz[alanthracene and benzolalpyrene altered the metabolism of E2 as determined from the radiometric (tritium release) and gas chromatography-mass spectrometry (GC-MS) assays. This alteration in E2 metabolism was accompanied by aberrant proliferation and abrogation of apoptosis as determined by the extent of replicative DNA synthesis, S-phase fraction and Sub Go (apoptotic) peak. Exposure of carcinogen-initiated cultures to 13C resulted in induction of C2-hydroxylation of E2 and of apoptosis and downregulation of hyperproliferation. Determination of altered cellular metabolism of E2 in response to initiators and modulators of carcinogenesis and evaluation of cell cycle related markers for proliferation and apoptosis may provide a mechanism-oriented approach to validate E2 metabolism as an endocrine biomarker for induction and prevention of human mammary carcinogenesis. -Environ Health Perspect 105(Suppl 3): 559-564 (1997) 
Introduction
Breast cancer is one of the prevalent causes Laboratory investigations on animal of death in women in the United States. models have provided compelling but cirThe American Cancer Society has estimated cumstantial evidence that human mammary a 31% incidence of breast cancer (184,300 carcinogenesis may be a multifactorial and new breast cancer cases) and about 17% multistep process involving early-occurring mortality (44,300 cancer related deaths) in molecular, biochemical, and cellular events 1996 (1) . These estimates emphasize a need that represent preneoplastic transformation to identify markers for risk, early detection, and late-occurring epigenetic events that and effective prevention.
represent promotion and progression of the preneoplastic phenotype to tumorigenic phenotype with metastatic potential (2, 3) . Identification and validation of biomarkers for preneoplastic transformation, therefore, may provide important leads not only for identifying markers of risk for developing breast cancer but also for evaluating effective primary or secondary prevention (4) (5) (6) (7) (8) (9) .
In the estrogen-responsive mammary tissue, the natural estrogen 171-estradiol (E2), in concert with other steroid and polypeptide hormones that have mammotropic or lactogenic effects, supports epithelial cell proliferation and neoplastic transformation (6) (7) (8) . The mitogenic stimulus mediated via E2 may predispose nontransformed cells for initiation of carcinogenesis, while in preinitiated cells, this stimulus may promote the expression of the transformed cell phenotype (2, 3, (5) (6) (7) (8) (10) (11) (12) .
The cellular biotransformation of E2 represents a complex enzymatic process by which metabolically competent cells convert the mitogenic estrogen E2 to its less active metabolites. Cytochrome P450 (cyp450)-dependent steroid hydroxylases are critical for E2 metabolism, while estrogen receptor, a nuclear transcription factor, is indispensable for transcriptional activation, expression of early response genes cfos, c-jun, c-myc, and resultant E2-mediated positive regulation of growth (12) (13) (14) (15) (16) .
Our studies on murine mammary explant cultures and on immortalized nontumorigenic mammary epithelial cell cultures have demonstrated that treatment with chemical carcinogens and transfection with oncogenes results in altered cellular metabolism of E2 and aberrant hyperproliferation in vitro prior to tumorigenicity in vivo (17) (18) (19) . In these studies alteration in E2 metabolism was detected by specific and significant increase in C16a-hydroxylation, with a concomitant decrease in C2-hydroxylation pathways, while aberrant hyperproliferation was quantified by the relative extent of cell proliferation in anchoragedependent and anchorage-independent conditions of growth. Altered cellular metabolism of E2 and aberrant hyperproliferation, therefore, represent biochemical and cellular surrogate end point biomarkers for mammary carcinogenesis (4, 9, (17) (18) (19) (20) (21) (2, 4, (17) (18) (19) . The tissue culture technology and biomarker assays established for the murine models have been optimized for human mammary tissue (4, 22, 23) .
The explant cultures were prepared from human mammary terminal duct lobular unit (TDLU) obtained from surgical samples. The TDLU are the endocrine responsive and proliferatively active intact organoids that represent target tissue for carcinogenesis (2, 4, 8) . These organoids were maintained in a chemically defined, serum-free Waymouth's MB 752/1 medium (GIBCO/BRL, Grand Island, NY) supplemented with 5 pg/ml insulin, 1 ng/ml E2, 2 mM L-glutamine, and antibiotics. The medium was routinely changed every 48 hr and the cultures were maintained in a humidified atmosphere of 95% air: 5% CO2 at 37°C.
The human mammary epithelial 184-B5 cell line was maintained in chemically defined, serum-free KBM-MEM medium (Clonetics Corp., San Diego, CA, and GIBCO/BRL) supplemented with 10 pg/ml insulin, 10 ng/ml epidermal growth factor, 10 pg/mI transferrin, 0.5 pg/ml hydrocortisone, and 5 pg/ml gentamycin (24, 25 (3, 10, (26) (27) (28) .
Cellular Metabolism of173-estradiol The metabolism of E2 by TDLU and 184-B5 cultures was determined by the radiometric assay that measures the tritium exchange from specifically labeled E2 to form 3H20 (4, 17, 19) and by the gas chromatography-mass spectrometry (GC-MS) assay that involves product isolation and identification of the metabolites (29) .
For the radiometric assay, cultures were incubated with 8 B5 cell culture system, treatment with 50 pM I3C exhibited 29.7 ± 0.7% S-phase fraction, 15.5 ± 0.6% apoptosis, and a C2/C16a-hydroxylation ratio of 4. Figure  2A,B) . Thus, the ability of I3C to inhibit the effect of B[a]P may, in part, be due to growth regulation by decreased proliferation, increased apoptosis, and increased C2-hydroxylation of E2.
The effect of DMBA appears to be distinct from that of B[a]P in the present experimental system. It will therefore be of considerable interest to examine whether 13C in DMBA initiated cells downregulates the status of S-phasespecific gene expression.
Discussion
The experiments in this study were conducted on in vitro models for human mammary (2, 18, (31) (32) (33) (34) (35) .
In the multistep process of mammary carcinogenesis, the natural estrogen E2 functions as a potent tumor promoter, acting prevalently during the late-occurring, postinitial (promotional) stage of tumorigenesis (3, 6, 7, 10 (27, 31) . Furthermore, 13C has been reported to induce C2-hydroxylation of E2 in human mammary carcinoma cells as well as in human subjects (42) (43) (44) (45) (31) . These observations, taken together, raise the possibility that increased production of antiproliferative E2 metabolite 2-OHE1 by 13C in carcinogen-initiated human mammary tissue may negatively regulate aberrant hyperproliferation, in part by induction of cellular apoptosis.
In conclusion, the pre §ent study on human mammary tissue-derived in vitro models for carcinogenesis has provided evidence that E2 metabolism and cell cyclerelated markers for proliferation and apoptosis may represent valuable surrogate end point biomarkers to evaluate efficacy of chemopreventive agents for human mammary carcinogenesis.
